Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 9/20 | 0.73 |
| ▸ | CNR1 | P21554 | 6/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29387064 | 1.00 | CNR2 (0.73) | CNR2CNR1 | |
| SCHEMBL15112081 | 0.85 | CNR2 (0.80) | CNR2CNR1 | |
| SCHEMBL29361900 | 0.84 | CNR2 (1.00) | CNR2CNR1 | |
| SCHEMBL1707018 | 0.84 | CNR2 (1.00) | CNR2CNR1 | |
| SCHEMBL11983311 | 0.84 | CNR2 (0.78) | CNR2CNR1 | |
| SCHEMBL15703451 | 0.83 | CNR1 (0.78) | CNR2CNR1 | |
| SCHEMBL16280633 | 0.83 | CNR2 (0.76) | CNR2CNR1 | |
| SCHEMBL15996044 | 0.83 | CNR2 (0.76) | CNR2CNR1 | |
| SCHEMBL16201691 | 0.83 | CNR2 (0.98) | CNR2CNR1 | |
| SCHEMBL29361944 | 0.83 | CNR1 (0.78) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250186363-A1 | Pharmaceutical Compositions and Methods for Treating Parkinson's Disease | PIKE THERAPEUTICS INC (CA) | 2025-06-12 | — | — | US | disclosed |
| EP-4558135-A1 | CONTINUOUS DELIVERY SYSTEMS COMPRISING A CANNABINOID AND MEDICINAL USES THEREOF | Pike Therapeutics Inc. (CA) | 2025-05-28 | — | — | EP | disclosed |
| US-12268699-B2 | Transdermal delivery of tetrahydrocannabinol | Pike Therapeutics Inc. (CA) | 2025-04-08 | — | — | US | disclosed |
| US-12121617-B2 | Transdermal delivery of cannabidiol | Pike Therapeutics Inc. (CA) | 2024-10-22 | — | — | US | disclosed |
| US-12097293-B2 | Transdermal delivery of cannabidiol | Pike Therapeutics Inc. (CA) | 2024-09-24 | — | — | US | disclosed |
| US-11938166-B2 | Methods and compositions for treating mucosal tissue disorders | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2024-03-26 | — | — | US | disclosed |
| EP-4326252-A1 | TRANSDERMAL PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF CHRONIC PAIN | Pike Therapeutics, Inc. (CA) | 2024-02-28 | — | — | EP | disclosed |
| EP-4322931-A1 | TRANSDERMAL DELIVERY OF CANNABIDIOL | Pike Therapeutics Inc. (CA) | 2024-02-21 | — | — | EP | disclosed |
| WO-2024018420-A1 | CONTINUOUS DELIVERY SYSTEMS COMPRISING A CANNABINOID AND MEDICINAL USES THEREOF | Pike Therapeutics Inc. (CA) | 2024-01-25 | — | — | WO | disclosed |
| EP-4255416-A1 | TRANSDERMAL PHARMACEUTICAL FORMULATIONS COMPRISING CBD OR THC FOR THE TREATMENT OF CANCER | Pike Therapeutics Inc. (CA) | 2023-10-11 | — | — | EP | disclosed |
| WO-2021074790-A1 | TRANSDERMAL DELIVERY OF CANNABIDIOL | PIKE THERAPEUTICS, INC., 1219014 B.C. LTD. (CA) | 2021-04-22 | — | — | WO | disclosed |
| US-20210106540-A1 | TRANSDERMAL DELIVERY OF CANNABIDIOL | Pike Therapeutics Inc. (CA) | 2021-04-15 | — | — | US | disclosed |
| EP-3698785-A1 | COMPOSITIONS COMPRISING A CANNABINOID RECEPTOR BINDING LIGAND | Novaliq GmbH (DE) | 2020-08-26 | — | — | EP | disclosed |
| US-20200179478-A1 | METHODS AND COMPOSITIONS FOR TREATING MUCOSAL TISSUE DISORDERS | UNIV NORTH CAROLINA CHAPEL HILL (US) | 2020-06-11 | — | — | US | disclosed |
| US-20190343793-A1 | COMPOSITIONS COMPRISING A CANNABINOID RECEPTOR BINDING LIGAND | NOVALIQ GMBH (DE) | 2019-11-14 | — | — | US | disclosed |
| US-10406200-B2 | Methods and compositions for treating mucusal tissue disorders | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2019-09-10 | — | — | US | disclosed |
| EP-3247402-A1 | COMPOSITION AND METHODS TO IMPROVE STABILITY, DOSING, PHARMACODYNAMICS AND PRODUCT SHELF LIFE OF ENDOCANNABINOIDS, PHYTOCANNABINOIDS AND SYNTHETIC CANNABINOIDS DELIVERED BY NASAL INHALER | Willinsky, Michael (CA) | 2017-11-29 | — | — | EP | disclosed |
| US-20160228490-A1 | METHODS AND COMPOSITIONS FOR TREATING MUCUSAL TISSUE DISORDERS | UNIV NORTH CAROLINA CHAPEL HILL (US) | 2016-08-11 | — | — | US | disclosed |
| US-9308234-B2 | Methods and compositions for treating mucosal tissue disorders | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2016-04-12 | — | — | US | disclosed |
| US-20150010654-A1 | Methods and Compositions for Treating Mucosal Tissue Disorders | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2015-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12097293-B2 | Transdermal delivery of cannabidiol | CNR2, CNR1, TRPV1 | CNR2 1/4885CNR1 2/4885 |
| US-12121617-B2 | Transdermal delivery of cannabidiol | CNR2, CNR1, TRPV1 | CNR2 1/4885CNR1 2/4885 |
| US-20210106540-A1 | TRANSDERMAL DELIVERY OF CANNABIDIOL | CNR2, CNR1, TRPV1 | CNR2 1/4885CNR1 2/4885 |
| US-20250186363-A1 | Pharmaceutical Compositions and Methods for Treating Parkinson's Disease | PARK7, SNCA, COMT | CNR2 422/4885CNR1 613/4885 |
| US-12268699-B2 | Transdermal delivery of tetrahydrocannabinol | CNR2, CNR1, OPRL1 | CNR2 1/4885CNR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.